Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28028545 | 0.85 | KDM4E (0.54) | HTTADRB2ADRB1LMNAHTR1A | |
| SCHEMBL2848420 | 0.84 | ADRA2C (0.43) | HTTADRB2ADRB1LMNAHTR1A | |
| SCHEMBL14695733 | 0.84 | GABRA1 (0.53) | GABRA1GABRB2HTTKDM4EALDH1A1 | |
| SCHEMBL3458335 | 0.82 | GABRA1 (0.51) | GABRA1GABRB2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL2846372 | 0.82 | KDM4E (0.42) | HTTADRB2ADRB1LMNAHTR1A | |
| SCHEMBL2847330 | 0.81 | HTT (0.44) | HTTADRB2ADRB1LMNAHTR1A | |
| SCHEMBL2849190 | 0.81 | ALDH1A1 (0.42) | HTTADRB2ADRB1LMNAHTR1A | |
| SCHEMBL2849222 | 0.81 | ADRA2C (0.41) | HTTADRB2ADRB1LMNAHTR1A | |
| SCHEMBL10433454 | 0.80 | KDM4E (0.56) | GABRA1GABRB2HTTKDM4EALDH1A1 | |
| SCHEMBL2845720 | 0.80 | MCHR1 (0.46) | HTTADRB2ADRB1LMNAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9497963-B2 | Methods and compositions for control of gypsy moth, Lymantria dispar | SIMON FRASER UNIVERSITY (CA) | 2016-11-22 | — | — | US | disclosed |
| US-20130045178-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTH, Lymantria dispar | SIMON FRASER UNIVERSITY (CA) | 2013-02-21 | — | — | US | disclosed |
| US-20100297059-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, LYMANRIA DISPAR | SIMON FRASER UNIVERSITY (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100190865-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, Lymanria dispar | SIMON FRASER UNIVERSITY (CA) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045178-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTH, Lymantria dispar | L3MBTL3, L3MBTL4, L3MBTL1 | GABRA1 356/4885GABRB2 263/4885HTT 2933/4885 |
| US-20100190865-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, Lymanria dispar | L3MBTL3, L3MBTL4, L3MBTL1 | GABRA1 618/4885GABRB2 473/4885HTT 2726/4885 |
| US-20100297059-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, LYMANRIA DISPAR | L3MBTL3, L3MBTL4, L3MBTL1 | GABRA1 656/4885GABRB2 500/4885HTT 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.